Font Size
Conference At A Glance
| SATURDAY, MAY 22, 2010 | ||
| 6:00PM-7:30PM | Opening Ceremony | TBN |
| 7:30PM- 9:00PM | Welcome Reception | |
| SUNDAY, MAY 23, 2010 | ||
| 8:00AM- 9:00AM | PLENARY | |
| State of the ART for Microbicides | Robin Shattock | |
| Taking it to the Streets | Vuyiseka Dubula | |
| 9:00AM-9:30AM | BREAK | |
| 9:30AM-11:15AM | Oral Abstracts: Pregnancy and HIV Risk in Microbicide Trials | |
| Pregnancy Incidence and Outcomes in Women Using Candidate Vaginal Microbicides PRO2000 and BufferGel: Results of the HPTN 035 Trial | Lisa A. Maslankowski | |
| Pregnancy among women in HIV-discordant relationships enrolled in a HIV prevention trial in Kisumu, Kenya | J. B. Odoyo | |
| Improving contraceptive uptake and reducing pregnancy rates in a microbicide trial | S. Sibeko | |
| Predictors of Pregnancy Among HPTN 035 Participants in Lusaka, Zambia | Sarah T. Roberts | |
| Impact of Becoming HIV+ on Contraceptive Use in the MIRA Trial | Kelly Blanchard | |
| Pregnancy is Associated with an Increased Risk for HIV Transmission among African HIV-1 Serodiscordant Couples | Nelly Mugo | |
| Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas | Richard Beigi | |
| 9:30AM-11:00AM | Mini-Symposia : Measuring Adherence in Prevention Studies | |
| Use of Telephone and Web-based Technology to Monitor Adherence | Ana Ventuneac | |
| Advances in Adherence Monitoring | Steven Asiimwe | |
| Pharmacokinetic Assessment of Adherence | Craig Hendrix | |
| 9:30AM-11:00AM | Oral Abstracts : Identifying Participants for HIV Prevention Trials | |
| Willingness to Participate in a Vaginal Microbicide Trial among Women in Kisumu, Kenya | Hellen Awuoche | |
| Willingness and covert use of vaginal microbicides by male partners of women participating in a cross-sectional survey | Rewa Kohli | |
| Assessing Yields of Recruitment Strategies for an HIV Prevention Trial Among HIV Discordant Couples in Kenya | P. Michira | |
| Recruiting and Retaining Participants in the Durban MDP 301 Trial Sites: Challenges and Strategies | Philisiwe Buthelezi | |
| Impact of Community Education on Accrual in the VOICE study: Zimbabwe Experience | C.Mashoko | |
| Identifying High and Low Risk MSM for HIV Prevention Trials | TBN | |
| 9:30AM-11:00AM | Oral Abstracts : Preclinical Studies of New Molecules for HIV Prevention | |
| L’644, a cholesterol derivatized version of the gp41 fusion peptide C34, provides superior activity in preclinical microbicide assays. | Sarah Harman | |
| Searching for New Inhibitors Disrupting gp41 Function as Microbicides for the Prevention of HIV Infection. | Stanislaw Pikul | |
| Anti-HIV Activity of the Candidate Microbicide Maraviroc, a CCR5 receptor antagonist | Patricia Fletcher | |
| Combinations of maraviroc and reverse transcriptase inhibitors as potential microbicides | Carolina Herrera | |
| Protection Against Repeated Vaginal SHIV Exposures in Macaques by a Topical Gel with an Integrase Inhibitor | Charles Dobard | |
| Protease Inhibitors Darunavir, Lopinavir and Ritonavir as Potential Microbicides | Abbey Evans | |
| 11:00AM-11:30AM | BREAK | |
| 11:30AM-12:45PM | Oral Abstracts : Learning from 1st Generation Products: N-9, PRO 2000, and Cellulose Sulfate | |
| Inflammatory response in the lower genital tract does not reflect vaginal drug exposure or impact | Courtney A. Schreiber | |
| Assessing the safety of PRO2000 vaginal gel in the MDP301 Phase III microbicide trial | Sheena McCormack | |
| Bridging the Gap between Preclinical Studies and the Performance of Microbicides in Large Scale Clinical Trials: A Reanalysis of Cellulose Sulfate | Theodore J Segarra | |
| Evaluation of 6% Cellulose Sulfate and 0.5% PRO2000 Gel Microbicide Efficacy in a Single-Dose Intravaginal R5+X4 SHIV Infection Model in Rhesus Macaques Pre-treated with Depo-Provera | Mohammed Saifuddin | |
| Assessing Markers of Inflammation after Vaginal Product Use: Nonoxynol-9, Cellulose Sulfate, and HEC Placebo Comparative Double-Blind Phase I Trial | Christine Mauck | |
| 11:30AM-1:00PM | Oral Abstracts: But Did They Like It? - An Update on Product Acceptability | |
| The LINK between Gel Properties and User Perceptions: Implications for Rational Design of Microbicides | Kathleen Morrow | |
| Acceptability of 0.5% PRO 2000 Gel and BufferGel in the HPTN 035 Microbicide Trial | Nicola Coumi | |
| Microbicides Acceptability: The Influence of Social and Cultural Norms, Interpersonal Relations and Sexual Socialization | Sharon Abbott | |
| Factors Affecting Acceptability and Adherence of a Candidate Microbicide Gel among High-Risk Women in Africa and India | Elizabeth Greene | |
| 11:30AM-1:00PM | Mini-Symposia: For Whom and How - Partnerships in Prevention | |
| Developing Models of HIV Prevention Advocacy | Jim Pickett | |
| Creating Research Partnerships with the Community - A Site Perspective. | Sanjay Mehendele | |
| Research Literacy for the Community and Community Literacy for Researchers. | Tabita Mahlangeni | |
| 11:30AM-1:00PM | Oral Abstracts: Pharmacokinetics | |
| Pre-treatment with Depo-Provera modifies the pharmacokinetics of CMPD167 in rhesus macaques following vaginal ring administration | Karl Malcolm | |
| Temporal Association of Protection by Carraguard-based Gels Containing MIV-150 After Single Versus Repeated Vaginal Application in Macaques | Meropi Aravantinou | |
| Protection by TFV gel Against Vaginal SHIV Infection in Macaques Three Days after Gel Application and Its Relationship to Tissue Drug Levels | Charles W Dobard | |
| The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques | Jeremy Nuttall | |
| Pilot Clinical Pharmacokinetic and Pharmacodynamic Study of UC781 Vaginal Gel | Jill Schwartz | |
| SPL7013 Gel (VivaGel®) Retains Potent Antiviral Activity Against HIV-1 and HSV-2 Following Vaginal Administration in Humans | Clare F. Price | |
| 1:00PM-2:00PM | LUNCH | |
| 2:00PM-3:00PM | POSTER VIEWING | |
| 3:00PM-3:50PM | Poster Discussion : Rectal Microbicides - From Development to Implementation | |
| Using drug combinations to design effective colorectal microbicides: where is the limit? | Carolina Herrera | |
| PC-815 Blocks Rectal Transmission of SHIV-RT When Applied 4 Hours Prior to Virus Challenge | Rachel Singer | |
| In vivo detection of microbicide induced damage in small animal rectal epithelium using confocal microendoscopy | Gracie Vargas | |
| Twenty-Eight Day Repeat Dose Toxicology Studies of UC781 Vaginal Gel in Sprague-Dawley Rats and New Zealand White Rabbits Following Rectal Administration | Timothy J. McCormick | |
| Sexual practices of MSM in Nigeria and interest in Microbicide | Ijeoma Nnaji | |
| 3:00PM-4:00PM | Poster Discussion : Thinking Outside the Box - Novel Drug/Approaches for HIV Prevention | |
| Cationic Cell Penetrating Peptides Inhibit HIV-1 Infection | Shawn Keogan | |
| Development of Flavonoids for Use in a Combination Microbicide | Charles Isaacs | |
| Design and Synthesis of Variants of the HIV-1 Aptamer, UCLA1 that binds to gp-120 | Brian Sproat | |
| Identification of anti-lipopolysaccharide factor (ALF) from the hemocytes of mud crab Scylla serrata: A promising molecule having anti-STI and anti-HIV activities | KVR Reddy | |
| Two Medicines That Block HIV-1 Gene Expression And Kill HIV-1 – Infected Cells Preferentially, Yet Lack Epithelial Toxicity. | Hartmut M Hanauske-Abel | |
| Driving HIV into suicide – a new approach for a microbicide | Karen Moelling | |
| 3:00PM-4:00PM | Poster Discussion : How Safe is Safe? | |
| A new model for studies on cervicovaginal inflammation and barrier disruption | Caitlin Blaskewicz | |
| Mechanisms of Cellulose Sulfate Interaction with the Human Bacteria-Colonized Cervicovaginal Epithelium - Use of a New In-vitro Model to Assess Microbicide Safety | Raina N. Fichorova | |
| Microbicide Excipients that Increase Susceptibility to Genital Herpes | Richard Cone | |
| In vitro evaluation of the safety profile of pharmaceutical excipients for the use in microbicide formulations | Youssef Gali | |
| Repeated Agent Exposures Affect In Vitro and In Vivo Measures of Microbicide Safety | Karissa Lozenski | |
| 3:00PM-4:00PM | Poster Discussion: Sex, HIV, and Biomarkers | |
| Characterization of Seminal Enhancer of Viral Infectivity (SEVI) on HIV-1 Penetration in the Female Genital Tract | Shannon Allen | |
| Broad Spectrum Endogenous Antimicrobials in Secretions from Female Reproductive Tract Epithelial Cells in Culture | Mimi Ghosh | |
| Molecular Mechanisms Mediating Proinflammatory Responses in Human Vaginal Epithelium | Theresa Joseph | |
| Optimising Endocervical Mucosal Cell Sampling for the Study of HIV Mucosal Target Cells in Microbicide and Mucosal Vaccine Research | Vicky Jespers | |
| Interlaboratory Variability in Detection of Cytokines by Bioluminex: Implications for Microbicide Safety Studies | Betsy Herold | |
| 4:30PM-6:00PM | Oral Abstracts : Rectal Microbicides: Preclinical Studies | |
| Expression of Membrane Drug Transporters in Recto-Sigmoid Colon from HIV Infected Men: Potential Role in Microbicide Permeability | María Fabiana De Rosa | |
| Effect of storage conditions on GALT T cell phenotype – implications for Phase 1 microbicide studies | Ian McGowan | |
| Assessing Colonic Epithelial Injury and HIV penetration following Simulated Ejaculation of Autologous Seminal Fluid in Men Who Have Sex with Men | Edward Fuchs | |
| Testing Rectal Safety of Tenofovir in the Macaque Model | Dorothy Patton | |
| 4:30PM-6:00PM | Oral Abstracts : The Legacy of Study Participation: Social Harms, Seroconverters and Site Capacity | |
| Social Harms in HPTN 035 in Lusaka, Zambia | Venerandah L. Nhandu | |
| Uptake of referrals to HIV care and treatment services in Mwanza, Tanzania during the MDP 301 Phase III clinical trial of PRO 2000 microbicide gel | Shelley Lees | |
| SPARTAC (Short Pulse AntiRetroviral Therapy at SeroConversion | Nonhlakanipho P. Makeka | |
| Long-term Follow up of HIV Seroconverters in Microbicide Trials – MTN 015 | Sharon Riddler | |
| What happens to sites after a trial; a case study from Nigeria | N. Onyejepu | |
| 4:30PM-6:15PM | Oral Abstracts: Adherence in Microbicide Trials | |
| Development of a "Smart Applicator" for Vaginal Delivery of Microbicide Gels Can Help In Monitoring Adherence to Clinical Trial Protocol | D Fairhurst | |
| Predictors of adherence in the Carraguard Phase 3 trial in South Africa | Barbara Friedland | |
| The Performance of the Population Council Applicator Test in a Simulated Microbicide Trial | Sarah Littlefield | |
| Feasibility and utility of returning used and unused applicators in microbicide trials: Experiences in CAPRISA 004 | Anushka Naidoo | |
| Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial | Barbara Mensch | |
| The 'Wisebag': an innovativestrategy for enhancing measurement of microbicide gel use in clinical trials | Tanuja Gengiah | |
| Daily monitored adherence as a possible adherence enabler in microbicide trials | Annalene Nel | |
| 4:30PM-6:00PM | Mini-Symposia: Product Selection Strategies | |
| Product Selection - An Industry Perspective | Louise Pedneault | |
| Presentation of Product Profiles | Randy Tressler | |
| Round Table Discussion of Products and Criteria for Advancing Products to Later Stage Development | Zeda Rosenberg | |
| Henry Gabelnick | ||
| Yasmin Halima | ||
| Stephen Becker | ||
| MONDAY, MAY 24, 2010 | ||
| 8:00AM-9:00AM | PLENARY | |
| From Transmission to Targets: How HIV Infects Mucosal Tissue | Ashley Haase | |
| Not Just a Handmaiden: The Role of Social Science in Microbicides and Other HIV Prevention Research | Judy Auerbach | |
| 9:00AM-9:30AM | BREAK | |
| 9:30AM-11:00AM | Oral Abstracts : Innovative Preclinical Studies | |
| DC-SIGN Increases the Affinity of HIV-1 Envelope Glycoprotein Interaction with CD4 | Karolin Hijazi | |
| Electrophoretic Mobility Reveals Conformational Changes in HIV-1 Env That Model Male to Female Transmission Events | D. Stieh | |
| Evaluation of ARV-based microbicides, alone and in combination, against drug resistant HIV-1 transmission in vitro. | Susan M. Schader | |
| A Preclinical Evaluation of the Small Molecule Entry Inhibitor DS003 as a Potential Microbicide | S. Harman | |
| Degradation of Naturally occurring and engineered antimicrobial peptides by proteases | B. J. Moncla | |
| Dual-chamber Model for Assessment of Pharmacodynamics and Bioavailability of Candidate Microbicides | Betsy Herold | |
| 9:30AM-11:00AM | Mini-Symposia : How Good is Good Enough? | |
| Population Effectiveness and Public Health | Marie-Claude Boily | |
| Balancing Microbicide Efficacy with Community Availability | Samukeliso Dube | |
| How Good is Good Enough – A Regulatory Perspective | Rajen Misra | |
| 9:30AM-11:00AM | Oral Abstracts: Formulation Science | |
| User-Identified Vaginal Gel Characteristics: A Qualitative Exploration of Perceived Product Efficacy | Kathleen Morrow | |
| Use of a Weak Buffer Does Not Adversely Impact Osmolality and Rheological Properties of a Vaginal Gel | Jeremy Nuttall | |
| Design of Novel Solid Vaginal Dosage Form of Dapivirine NNRTI and BMS-599793 (DS003) Entry inhibitor in Combination | Sanjay Garg | |
| Simultaneous Optical Detection of Intravaginal Gel Coating, Dilution, Drug Distribution, and Tissue Integrity in Women | Tyler Drake | |
| Multivariate computational model to help rate microbicide gel performance: combining vaginal distribution, drug delivery and acceptability | David F Katz | |
| 9:30AM-11:00AM | Oral Abstracts: Preclinical studies of Ring and Film Formulations | |
| Formulation Development of Matrix-Type Silicone Elastomer Vaginal Rings Containing Protease Inhibitors | Susan Fetherston | |
| Combination Ethylene Vinyl Acetate Intravaginal Vaginal Rings Containing Dapivirine and Maraviroc | Andrew Loxley | |
| In vitro and in vivo release of tenofovir from silicone intravaginal rings | Tom Smith | |
| In vivo Safety Study in Macaca fascicularis on Matrix-Type Silicone Elastomer Vaginal Rings Loaded With Saquinavir | Susan Fetherston | |
| Dapivirine vaginal ring design and drug load effects on in vitro drug release and intravaginal drug distribution in women | J. W. Romano | |
| Vaginal Film Drug Delivery of the Pyrimidinedione IQP-0528 for the Prevention of HIV Infection | Anthony S. Ham | |
| 11:00AM-11:30AM | BREAK | |
| 11:30AM-1:00PM | Oral Abstracts: Vaginal Practices and Barriers | |
| Intravaginal Practices Among Female Sex Workers in Kibera, Kenya | Maria F. Gallo | |
| The Duet cervical barrier used continuously or pre-coitally for HIV prevention in Zimbabwean women: an acceptability and safety study | Elizabeth T. Montgomery | |
| Vaginal Practices, Gel and Barrier Methods Use Among HIV Prevention Trial Participants Southern Africa | Ariane van der Straten | |
| How many women really achieve consistent condom use over the course of a year? Evidence from rural KwaZulu-Natal. | Mitzy Gafos | |
| 11:30AM-1:00PM | Oral Abstracts: Looking for Answers: Trial Design, Outcomes, and Mathematical Modeling | |
| Adaptive Design Considerations in Planning the CAPRISA 004 Study | Anneke Grobler | |
| Appropriateness of Hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: A comparison of the two control arms of HPTN 035 | Barbra Richardson | |
| Discrepancies between the outcomes of two recent HIV microbicide trials evaluating the effectiveness of 0.5% PRO 2000 | Benoît R. Mâsse | |
| Should oral PrEP and microbicide randomised trials be powered to rule out products with efficacy of 0% or greater? | Dobromir Dimitrov | |
| Are Vaginal Microbicides Cost-effective? | Stéphane Verguet | |
| Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP) | Ume Abbas | |
| 11:30AM-1:00PM | Mini-Symposia: A Tale of Two Compartments | |
| Non Human Primate Studies of Rectal and Vaginal Safety and Efficacy | Dorothy Patton | |
| Compartment Specific Pharmacokinetics | Angela Kashuba | |
| Does Africa Need Rectal Microbicides? | Salim Abdool Karim | |
| 11:30AM-1:00PM | Oral Abstracts : Animal Models of Safety and Effectiveness | |
| Quantitative image-based assessment of microbicide-induced damage in the ovine vaginal epithelium using confocal microendoscopy | Gracie Vargas | |
| PC-1005, A Novel Broad-Spectrum Microbicide Candidate, Completely Protects Rhesus Macaques Against Vaginal SHIV-RT Challenge | Jessica Kenney | |
| Film-formulated Retrocyclin RC-101, Applied Topically to the Vagina of Pigtailed Macaques, is Retained Mucosally and Remains Active Against HIV-1 | Alexander M. Cole | |
| A Macaque Vaginal Explant /RT-SHIV Infection Model for Efficacy Study of Microbicides | Che-Chung Tsai | |
| Post Coital Assessments: Potential for Macaque Safety Model Expansion | Dorothy Patton | |
| 1:00PM-2:00PM | LUNCH | |
| 2:00PM-3:00PM | POSTER VIEWING | |
| 3:00PM-4:00PM | Poster Discussion: Integrating Contraception and HIV Prevention | |
| Dual Protection Polyurethane Intravaginal Rings for the Simultaneous Delivery of Levonorgestrel and UC781 | Festo Damian | |
| Development of microbicide-releasing SILCS diaphragm | Ian Major | |
| Vaginal Delivery of UC781 in Woman’s Condom Capsules | Lindsay Ferguson | |
| Unmet family planning needs among HIV-positive participants screened for FEM-PrEP. | Jennifer Deese | |
| High uptake of non-barrier contraception by women before randomization into an HIV prevention trial in rural Kenya | Kenneth Ngure | |
| Pregnancy Rates in the Durban Site of the MDP 301 Trial: Implications for VOICE and Other PrEP Studies. | Zakir Gaffoor | |
| 3:00PM-4:00PM | Poster Discussion: Life Beyond Traditional Gels - Upcoming Drug Delivery Systems | |
| Phenylboronate-Salicylhydroxamate Crosslinked Hydrogels as a pH Responsive Microbicide Vaginal Drug Delivery Vehicle | Krisofer Langheinrich | |
| Novel non-aqueous silicone elastomer gels for practical formulation of HIV microbicides | Claire Forbes | |
| Quick Dissolve Films as Drug Delivery Systems for Combination Microbicides | Ayman Akil | |
| Development and Evaluation of Novel Solid Dosage Forms of Tenofovir | Sanjay Garg | |
| Design of an intravaginal ring for the simultaneous delivery of IQP-0528 and tenofovir | Justin Clark | |
| Production and Preservation of Highly Viable Lactobacillus for Mucosal Delivery of Therapeutics in Situ | Qiang Xu | |
| 3:00PM-4:00PM | Poster Discussion: In vitro/In vivo Evaluations: An Essential Bridge for Product Development | |
| Safety testing of silicone elastomer matrix vaginal rings containing UC781 and Tween 80 using Epivaginal (VEC-606) tissues | Christopher McConville | |
| MRI Evaluation of the Distribution and Retention of Multiparticulates in the Human Vagina | Samata Mehta | |
| In vitro release of tenofovir and acylclovir from a silicone vaginal ring platform | John Moss | |
| Assessing HIV-1 Cross-Resistance in vitro against RTI-based Microbicides Currently Under Development | Philippe Selhorst | |
| A two compartment in vitro release model for the testing of HIV microbicide formulations | Christopher McConville | |
| Modulation of epithelial innate immune function by T. vaginalis | Raina Fichorova | |
| 3:00PM-4:00PM | Poster Discussion: Clinical Trial Adherence, Acceptability, and Retention | |
| Biophysical & Behavioral Acceptability of Microbicides | Stéphane Verguet | |
| Socio-Behavioral Approaches to Maximize Adherence in a Phase 3 PrEP Trial | Amy Corneli | |
| Vaginal practices among Nigerian women and its implication for microbicide development and use | Oliver Ezechi | |
| Acceptability of Optical Coherence Tomography During a Clinical Study | Susan Rosenthal | |
| Innovative strategies in a Phase IIB Microbicide Trial results in high retention. Experiences from CAPRISA 004. | Frohlich Janet | |
| The Use of Quality Control Panels in Clinical Trials. | Tania Crucitti | |
| 4:30PM-6:15PM | Oral Abstracts: Biomarkers in the Female Genital Tract | |
| Gene expression profile of vaginal epithelial cells exposed to pro- immunoinflammatory agents. Identification of novel biomarkers of mucosal safety | Irina Zalenskaya | |
| Comparison of Swabs, Lavage, and Diluents to Quantify Candidate Biomarkers for Microbicide Safety and Genital Tract Mucosal Immunity | Charlene S. Dezzutti | |
| Anti-HIV Activity in Cervical-vaginal Secretions from HIV Positive and HIV Negative Women Correlates with Innate Antimicrobial Factors and Disease Progression | Mimi Ghosh | |
| Vaginal Distribution of Cell-Free and Cell-Associated HIV Surrogates Following Simulated Intercourse | Nicolette A. Louissaint | |
| A Phase I Study to Assess Genital Tract Mucosal Immunity Following Repeated Vaginal Application of 1% Tenofovir Gel | Marla J. Keller | |
| Colposcopy: Still useful in microbicide safety trials? | Christine Mauck | |
| Natural Variability of Phosphate Complicates Safety Monitoring in a Phase 2 Microbicide Trial | Katherine Bunge | |
| 4:30PM-6:00PM | Oral Abstracts: Communication of and Advocacy for HIV Prevention Clinical Trials | |
| Preparing participants for results of HIV prevention trials: an example from MDP 301 in northern KwaZulu-Natal, South Africa | Misiwe Mzimela | |
| Communications Challenges: How the Internet and 24-hour Media Affect Local Dissemination of Trial Results | Deborah Baron | |
| Preparing communities for results of HIV prevention trials: the case of communities participating in MDP 301 in Masaka, Uganda | Richard Hasunira | |
| The Joy of Tech: IRMA as a Model for Maximizing Electronic Communications to Build and Nurture an Advocacy Network | Jim Pickett | |
| Grassroots to Government: The Role of Community Advocates in Mobilizing Government Support for Microbicide and Prevention Research: Case Study of South Africa and Kenya | Samukeliso Dube | |
| 4:30PM-6:00PM | Oral Abstracts: Bridging to the Future | |
| The Microbicide Development Strategy | Polly Harrison | |
| Tools for Microbicide Development and How You Can Access Help | Phil Markham | |
| The CHAARM Program | Charles Lacy | |
| 4:30PM-6:00PM | Mini-Symposia: ART: Challenges, Pitfalls, and Opportunitie |
|
| Is it Time for Test and Treat? | Ken Mayer | |
| When Health Care Priorities Collide – Using Drugs for Treatment and Prevention. | Regina Osih | |
| Antiretrovirals for Treatment andPrevention – Two Trains on a Collision Course? | John Mellors | |
| 7:00PM-10:00PM | Reception - Phipps Conservatory | |
| TUESDAY, MAY 25, 2010 | ||
| 8:00AM-9:00AM | PLENARY | |
| Putting Vaccines Back into the Prevention Puzzle | Susan Buchbinder | |
| From Research to Reality: Implemenation of Biomedical Prevention | James McIntyre | |
| 9:00AM-9:30AM | BREAK | |
| 9:30AM-11:00AM | Oral Abstracts: STI's, Bacterial Vaginosis, and Lactobacilli | |
| Can We Quantitatively Follow up Lactobacillae Species with Real Time PCR Methods for the Safety Evaluation of Microbicides and Mucosal Vaccines? | Vicky Jespers | |
| Aptamers that neutralize Herpes Simplex Virus Type-2 as potential components of a multi-virus microbicide | Michael Moore | |
| Genital Secretions from HIV Infected Women Exhibit Decreased Activity against HSV-2 | Rebecca Pellett Madan | |
| Establishing and sustaining a healthy vaginal environment: results from a randomized trial of oral periodic presumptive treatment for vaginal infections | Jennifer E. Balkus | |
| Validity of Clinical Diagnosis of Bacterial Vaginosis by Human Immunodeficiency Virus Infection Status | Maria F. Gallo | |
| 9:30AM-10:50AM | Mini-Symposia: What Comes After Tenofovir? | |
| Designing Studies without a Placebo | Doug Taylor | |
| Alternative Antiretroviral Drugs for HIV Prevention | Daria Hazuda | |
| Combination Antiretroviral Microbicide Products | Joe Romano | |
| Combining HIV Prevention and Contraceptive Technologies | Gustavo Doncel | |
| 9:30AM-11:00AM | Oral Abstracts: Rectal Sex: Frequency and Impact | |
| Anal Intercourse among Female Sex Workers Participating in Microbicides Preparedness Studies in Mombasa, Kenya and Kigali, Rwanda | Nienke Veldhuijzen | |
| Interest of At Risk Boston Men Who Have Sex With Men in Oral and Topical Antiretroviral Chemoprophylaxis | Kenneth Mayer | |
| What impact could we expect at a community level from an effective rectal microbicide used my MSM in Peru? | Holly Prudden | |
| Potential impact on HIV transmission of a rectal microbicide used by men who have sex with men in southern India | Anna M Foss | |
| Safety and Anti-HIV Activity of Over-the-Counter Lubricant Gels | Charlene Dezzutti | |
| Rectal Lubricant Use and Risk for Rectal STI | Pamina Gorbach | |
| 9:30AM-11:00AM | Oral Abstracts : Consent, Ethics, and Community Participation | |
| Ongoing Informed Consent Comprehension Assessment: Results of a Pilot Conducted in HPTN 035 | Anne Coletti | |
| Using Informed Consent Quizzes to Determine Enrollment Eligibility and Level of Trial Understanding for HIV-negative Women in the FEM-PrEP Clinical Trial | Kevin McKenna | |
| “No Man Can Serve Two Masters”: The Intersection of Recruitment and Education by Community Educators | Nomampondo Barnabas | |
| UNAIDS Good participatory practice guidelines and principles implemented in the HPTN 035 trial | Neetha S Morar | |
| Empowering The Communities Through The Training of Laypersons On Ethics Board | Morenike Ukpong | |
| 11:00AM-11:30AM | BREAK | |
| 11:30AM-1:00PM | Oral Abstracts: Novel Approaches | |
| Lactic Acid is a Natural Microbicide with HIV Virucidal Activity | Gilda Tachedjian | |
| Functional Characteristics of MucoCept Lactobacillus Strains upon their Adherence to Human Cervical and Vaginal Epithelial Cells | Raina Fichorova | |
| Microbicide testing for effects on Lactobacillus species: appropriate methodology | B. J. Moncla | |
| Toward an RNAi-based microbicide: CD4 aptamer-siRNA chimeras inhibit HIV-1 infection in primary cells and in polarized human cervical explants | Lee Wheeler | |
| 5'-O-Fatty Acyl Ester Derivatives of 3'-Fluoro-2',3'-dideoxythymidine (FLT) as Microbicidal Agents | Keykavous Parang | |
| Intravaginal Gene Silencing Using Biodegradable Polymer Nanoparticles Densely Loaded with Small-Interfering RNA | Kim A. Woodrow | |
| 11:30AM-1:00PM | Mini-Symposia: Mice, Monkeys, and Humans | |
| Comparing Mice and Monkeys | Paul Denton | |
| Using Human Explants Mmodels to Predict Safety and Efficacy | Charlene Dezzutti | |
| Bridging Preclinical Observations to Phase 1 Clinical Trials | Peter Anton | |
| 11:30AM-1:00PM | Session Cancelled | |
| 11:30AM-1:00PM | Oral Abstracts: HIV Seroincidence - Finding the Communities at Risk | |
| HIV Seroconversion Patterns in MDP301 | Ute Jentsch | |
| Cross-Sectional Estimation of HIV Incidence by BED-CEIA and Avidity Index Assays in Vaginal Microbicide Preparedness Studies in Rwanda and South Africa | Janneke van de Wijgert | |
| Time to think locally: Investigating the “hot spots" for HIV infection in communities of Durban, South Africa which were targeted for Microbicide studies | Handan Wand | |
| Comparison of partner testing with home-based HIV counseling and testing (HBHCT) for recruitment of young sexually active HIV sero-discordant couples into an HIV prevention trial: A Case Study from Mbale, Uganda | J.L.Tumuhe | |
| Who Screens for HIV Prevention Research and How do they Compare with a Representative Community Sample? Implications for Microbicide Trials in South Africa | Mary H. Latka | |
| 1:00PM-2:00PM | LUNCH | |
| 2:00PM-3:00PM | POSTER VIEWING | |
| 3:00PM-4:00PM | Poster Discussion: Standards of Care in Prevention Trials | |
| How Much Is Enough?: Standards of Prevention in HIV Prevention Trials | Sean Philpott | |
| Common decimals on community perspectives on the ethical conduct of clinical trials: a review of the oral tenovofir controversy | Morenike Ukpong | |
| Addressing coercion in the conduct of clinical trials on microbicides | Kolawole Oyedeji | |
| Standards-of-care in microbicide trials: do research participants have special entitlements? | Bridget Haire | |
| Community Monitoring of the Rollout of Male Circumcision for HIV Prevention and its Implications for Women | Cindra Feuer | |
| 3:00PM-4:00PM | Poster Discussion: Sexual Behavior and HIV Prevention | |
| A comparison of peer–mediated HIV prevention interventions under different environments for female sex workers in Kenya | Peninah Mwangi | |
| Predictors of Delayed Sexual Debut among Youth in the in Nyanza Province, Kenya | Enos Ochieng | |
| Sexual networking in a Nigerian University: Implication for HIV transmission. | Babatunde Olaiya | |
| Unmet Need for Safe Sex Practice and Opportunities for Vaginal Microbicides among HIV Uninfected Female Sex Workers (FSW) in India | Malika Alexander | |
| Exploring Adolescent Girls’ Protection Strategies against HIV in Lusaka, Zambia | Martha Brady | |
| 3:00PM-4:00PM | Poster Discussion: Advocating for HIV Prevention | |
| Tapping into the Strength of Faith Based Organization an Effective Strategy in Promoting Microbicides | Sekoni Babtunde | |
| Microbicides in Spain: an experience of advocacy for new HIV/AIDS preventive tools | Gabriel Boichat | |
| Identifying priorities, gaps and opportunities in prevention research through community advocacy: How the AVAC-GCM HIV Prevention Research Advocates Fellowship Program is Nurturing Emerging Leaders | Manju Chatani | |
| New Prevention Technologies and sex workers: Protection for whom and at what price? | Anna Forbes | |
| Leveraging Web-based Technology to Build the Capacity and Knowledge of Advocates | Gary Wolnitzek | |
| 3:00PM-4:00PM | Poster Discussion: Partners and Prevention | |
| Behavioral Recall Accuracy in a Microbicide Trial: Effects of Psychological Stress, Serostatus and Timing of Interview | Kathleen M MacQueen | |
| Do Indian Men Want Their Spouses To Use Vaginal Microbicides? | Rewa Kohli | |
| I am forever scared: The Sexual and Reproductive Health Needs and Rights of Women Newly Diagnosed with HIV | Sharon Abbott | |
| Comparison of Socio-Behavioral Formative Data at Two Sites in Advance of the FEM-PrEP Clinical Trial | Laura Johnson | |
| Attitudes about Research Participation in Microbicide Studies | Susan Rosenthal | |
| 3:00PM-4:00PM | Late Breaker Session | |
| TBN | ||
| 4:00PM-5:00PM | Closing Ceremony | |
| TBN |